課程介紹
| View in browser |
 |
| Amivantamab Plus Lazertinib vs Osimertinib in First-line (1L) EGFR-mutant (EGFRm) Advanced NSCLC: Final Overall Survival (OS) from the Phase 3 MARIPOSA Study Martin Dietrich, MD, PhD and Roy Herbst, MD discuss how the evolving first-line treatment options for EGFR-mutated non-small cell lung cancer, including osimertinib monotherapy, osimertinib plus chemotherapy, and amivantamab plus lazertinib, have reshaped the landscape, with a strong emphasis on overall survival benefits and the role of combination therapies in improving patient outcomes. Watch Now |
|
Featured Video |
 |
| Impressions of MARIPOSA Overall Survival and Potential Impact in Current SOC Panelists discuss how the significant overall survival (OS) benefit demonstrated by the new combination therapy (amivantamab-lazertinib) compared with standard monotherapy makes it a preferred treatment option for most patients despite a slightly increased toxicity and time commitment. Watch Now |